The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Open accessAbstract
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, autoimmune, inflammatory disorder that typically affects the optic nerves and spinal cord. At least two thirds of cases are associated with aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage to the central nervous system. In a previous small, open-label study involving patients with AQP4-IgG-positive disease, eculizumab, a terminal complement inhibitor, was shown to reduce the frequency of relapse. METHODS: In this randomized, double-blind, time-to-event trial, 143 adults were randomly assigned in a 2:1 ratio to receive either intravenous eculizumab (at a dose of 900 mg weekly for the first four doses starting on day 1, followed by 1200 mg every 2 weeks starting at week 4) or matched placebo. The continued use of stable-dose immunosuppressive therapy was permitted. The primary end point was the first adjudicated relapse. Secondary outcomes included the adjudicated annualized relapse rate, quality-of-life measures, and the score on the Expanded Disability Status Scale (EDSS), which ranges from 0 (no disability) to 10 (death). RESULTS: The trial was stopped after 23 of the 24 prespecified adjudicated relapses, given the uncertainty in estimating when the final event would occur. The mean (±SD) annualized relapse rate in the 24 months before enrollment was 1.99±0.94; 76% of the patients continued to receive their previous immunosuppressive therapy during the trial. Adjudicated relapses occurred in 3 of 96 patients (3%) in the eculizumab group and 20 of 47 (43%) in the placebo group (hazard ratio, 0.06; 95% confidence interval [CI], 0.02 to 0.20; P<0.001). The adjudicated annualized relapse rate was 0.02 in the eculizumab group and 0.35 in the placebo group (rate ratio, 0.04; 95% CI, 0.01 to 0.15; P<0.001). The mean change in the EDSS score was -0.18 in the eculizumab group and 0.12 in the placebo group (least-squares mean difference, -0.29; 95% CI, -0.59 to 0.01). Upper respiratory tract infections and headaches were more common in the eculizumab group. There was one death from pulmonary empyema in the eculizumab group. CONCLUSIONS: Among patients with AQP4-IgG-positive NMOSD, those who received eculizumab had a significantly lower risk of relapse than those who received placebo. There was no significant between-group difference in measures of disability progression. (Funded by Alexion Pharmaceuticals; PREVENT ClinicalTrials.gov number, NCT01892345; EudraCT number, 2013-001150-10.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Self-citationRevised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
Self-citationThe spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Self-citationThe clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. F., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,822
Self-citationHauser, S. L., Dawson, D. M., Lehrich, J. R., Beal, M. F., Kevy, S. V., Propper, R. D., Mills, J. A., & Weiner, H. L. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301273080401 · Cited by 827
Saadoun, S., Waters, P., Bell, B. A., Vincent, A., Verkman, A. S., & Papadopoulos, M. C. (2010) · Brain · doi:10.1093/brain/awp309 · Cited by 548
Frigeri, A., Gropper, M. A., Umenishi, F., Kawashima, M., Brown, D., & Verkman, A. S. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.9.2993 · Cited by 400
Pittock, S. J., Lennon, V. A., McKeon, A., Mandrekar, J., Weinshenker, B. G., Lucchinetti, C. F., O'Toole, O., & Wingerchuk, D. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70076-0 · Cited by 395
Self-citationInhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., & Evans, M. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00078-8 · Cited by 363
Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes
Hinson, S. R., Romero, M. F., Popescu, B. F. G., Lucchinetti, C. F., Fryer, J. P., Wolburg, H., Fallier-Becker, P., Noell, S., & Lennon, V. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109980108 · Cited by 328
Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
Waters, P., Reindl, M., Saiz, A., Schanda, K., Tuller, F., Kral, V., Nytrova, P., Sobek, O., Nielsen, H. H., Barington, T., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312601 · Cited by 294
Self-citationNeuromyelitis Spectrum Disorders
Weinshenker, B. G., & Wingerchuk, D. M. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.12.014 · Cited by 286
Self-citationUpdated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica
Jiao, Y., Fryer, J. P., Lennon, V. A., Jenkins, S. M., Quek, A. M. L., Smith, C. Y., McKeon, A., Costanzi, C., Iorio, R., Weinshenker, B. G., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a6cb5c · Cited by 244
Self-citationICH harmonized tripartite guideline: Guideline for Good Clinical Practice.
(2001) · PubMed · Cited by 243
Bologna, L., Gotti, E., Manganini, M., Rambaldi, A., Intermesoli, T., Introna, M., & Golay, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000303 · Cited by 200
Nikoo, Z., Badihian, S., Shaygannejad, V., Asgari, N., & Ashtari, F. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8590-0 · Cited by 192
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
Kessler, R. A., Mealy, M. A., & Levy, M. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-015-0387-9 · Cited by 158
Self-citationMultiplicity Considerations in Clinical Trials
Dmitrienko, A., & D’Agostino, R. B. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1709701 · Cited by 140
Jeong, I. H., Park, B., Kim, S., Hyun, J., Joo, J., & Kim, H. J. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515587752 · Cited by 121
Self-citationNationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark
Papp, V., Illés, Z., Magyari, M., Koch‐Henriksen, N., Kant, M., Pfleger, C., Roemer, S. F., Jensen, M. B., Petersen, A. E., Nielsen, H. H., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006645 · Cited by 113
Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
Duan, T., Smith, A. J., & Verkman, A. S. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1333-z · Cited by 92
Autoimmune aquaporin-4 induced damage beyond the central nervous system
He, D., Zhang, A., Li, Y., Cai, G., Li, Y., & Guo, S. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.09.013 · Cited by 26
Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
Kitley, J., Leite, M. I., Elsone, L., Jacob, A., & Palace, J. A. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306541 · Cited by 7
Self-citation
Cited by
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Self-citationThe vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection
Pons, S., Fodil, S., Azoulay, E., & Zafrani, L. (2020) · Critical Care · doi:10.1186/s13054-020-03062-7 · Cited by 517
Traboulsee, A., Greenberg, B. M., Bennett, J. L., Szczechowski, L., Fox, E., Shkrobot, S., Yamamura, T., Terada, Y., Kawata, Y., Wright, P., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30078-8 · Cited by 513
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Self-citationTahara, M., Oeda, T., Okada, K., Kiriyama, T., Ochi, K., Maruyama, H., Fukaura, H., Nomura, K., Shimizu, Y., Mori, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30066-1 · Cited by 378
Self-citation
Metadata
- Authors
- Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J., Nakashima, I., Terzi, M., Totolyan, N., Viswanathan, S., Wang, K.-C., Pace, A., Fujita, K. P., Armstrong, R., & Wingerchuk, D. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-15
- Volume
- 381
- Issue
- 7
- Pages
- 614-625
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2943416206
- Cited by
- 872
- References
- 26
- FWCI
- 64.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.